scholarly journals Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia

2011 ◽  
Vol 58 (3) ◽  
pp. 185-191 ◽  
Author(s):  
Tadashi Yamakawa ◽  
Takeshi Kaneko ◽  
Erina Shigematu ◽  
Junko Kawaguchi ◽  
Kazuaki Kadonosono ◽  
...  
Author(s):  
Zainab H. Fathi ◽  
Jehan A. Mohammad ◽  
Marwah H. Mohammed

Adiponectin (APN) is an adipokine with anti-inflammatory and anti-atherogenic properties decreased in type 2 diabetes mellitus (T2DM) that may influence endothelial function by regulating serum nitric oxide (NO) levels. The current study aimed to investigate the effect of two oral hypoglycemic drugs, Metformin and Glibenclamide (GLC), on circulating APN and NO levels and to find a correlation between APN and NO levels in type 2 diabetic patients. Fifty males and females previously diagnosed with T2DM were conducted in this trial and classified into groups: Group A involved 18 untreated patients with T2DM, group B involved 16 patients receiving Metformin monotherapy (1000 mg/day) for up to 1 year and group C involved 16 patients receiving GLC (5 mg/day) for up to 1 year. Circulating APN and NO were measured. Compared to GLC, Metformin therapy showed a significant increase in APN and NO levels in type 2 diabetic patients. Our findings established that Metformin has a protective effect on endothelial function, including increased APN and NO bioavailability, beyond its glucose-lowering effect.


Diabetes Care ◽  
2005 ◽  
Vol 28 (5) ◽  
pp. 1132-1138 ◽  
Author(s):  
A. Mari ◽  
A. Gastaldelli ◽  
J. E. Foley ◽  
R. E. Pratley ◽  
E. Ferrannini

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Masashi Shimoda ◽  
Maiko Miyoshi-Takai ◽  
Shintaro Irie ◽  
Akihito Tanabe ◽  
Atsushi Obata ◽  
...  

Dipeptidyl peptidase-4 (DPP-4) inhibitors are often used all over the world and exert various beneficial effects including glucose-lowering effect in many subjects with type 2 diabetes. It is poorly understood, however, which factors are closely related with the durability of glucose-lowering effect by DPP-4 inhibitor. In this study, we examined retrospectively which factors could mainly influence the durability of DPP-4 inhibitor. We enrolled 212 participants with type 2 diabetes to whom DPP-4 inhibitor was administered for over 1 year without an addition or increase of other hypoglycemic agents. Age and baseline HbA1c level were significantly higher in the effective group than those in the ineffective group. The effective group had a tendency of smaller amounts of weight change, average total cholesterol, and average triglyceride compared with the ineffective group. Multiple logistic regression analysis showed that average triglyceride and baseline HbA1c were independent predictors associated with the durability of DPP-4 inhibitor. Moreover, an average triglyceride level contributed to the durability of DPP-4 inhibitor in the obese group (BMI ≥ 25 kg/m2) but not in the nonobese group (BMI < 25 kg/m2). These results suggest the importance of strict triglyceride management to maintain the durability of glucose-lowering effect by DPP-4 inhibitor, especially in obese subjects with type 2 diabetes.


Sign in / Sign up

Export Citation Format

Share Document